Abstract: Probiotics are increasingly used by consumers and practitioners to reduce gastrointestinal (GI) distress and improve gut function. Here, we sought to determine whether addition of supplemental bacteriophages (PreforPro) could enhance the effects of a common probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) on GI health. We conducted a 4-week, randomized, parallel-arm, double-blind, placebo-controlled trial where primary outcomes included self-assessments of GI inflammation (p=0.01) and a trending improvement in colon pain (p=0.08) in individuals consuming B. lactis with PreforPro, but not in the group consuming only the probiotic. There was also a larger increase in Lactobacillus and short chain fatty acid-producing microbial taxa detected in stool of participants taking PreforPro with B. lactis compared to the probiotic alone. Overall, these results suggest the addition of PreforPro as a combination therapy may alter gut ecology to extend the GI benefits of consuming B. lactis or other probiotics.

Keywords: bacteriophage, Bifidobacterium, gut microbiota, intestinal health, microbiome, probiotic
1. Introduction

Probiotics are live beneficial microorganisms that confer benefits to the host through a variety of mechanisms [1]. They are commercially available as over-the-counter dietary supplements and can be found as either natural components in many fermented foods, or supplemented additives in non-fermented food products. Probiotics are being explored as an accessible, convenient, and relatively low-cost strategy to modify the gut microbiota for a variety of human health outcomes ranging from improved gastrointestinal (GI) function to management of lipid and glucose metabolism [2]. While there is still minimal scientific evidence to support many of these uses, there are data supporting the efficacy of probiotics for improving GI function. Efficacy appears to be somewhat dependent on the specific species/strains, or the combination, used for a given condition; however, a 2012 meta-analysis of randomized controlled trials showed that 8 of the 11 species/mixtures tested were efficacious for a range of GI conditions, including pouchitis, infectious and C. difficile associated-diarrhea, Irritable Bowel Syndrome (IBS), and antibiotic-associated diarrhea [3]. A more recent meta-analysis suggests that probiotics may also be beneficial in alleviating functional constipation in adults [4]. Even in cases where there was insufficient data to demonstrate probiotic efficacy, adverse effects were minimal [5], suggesting probiotics are a low risk intervention to improve GI health in humans.

Prebiotics are dietary components that selectively enhance populations of specific beneficial bacteria, such as Lactobacillus and Bifidobacterium, which are common commensal organisms and are frequently found in supplemental probiotics. Although the traditional definition of prebiotics was limited to fiber-based dietary compounds [6], a recently expanded definition includes some non-fiber components, such as omega-3 fatty acids and phytochemicals, such as polyphenols, that selectively modify gut bacteria for improved human health outcomes [7]. We recently demonstrated that a group of E. coli-targeting bacteriophages showed bifidogenic effects after 4 weeks of oral supplementation in healthy adults, with no global disruption of the gut microbiota, suggesting they may act as prebiotics [8]. Bacteriophages, or phages, have the potential to allow beneficial bacteria to thrive due to their ability to selectively target, infect, and destroy pathogenic bacteria. Phages attach to a specific host bacterium, insert their genetic material into the cell, and take over the machinery of the host cell to replicate phage components. Once this process is complete, the cell is destroyed, or lysed, releasing new phage particles. Through this process, phages may reduce competition among commensal bacteria for limited resources and produce a potential fuel source in the form of contents released from the dead bacteria.

The combination of selected formulations of bio-therapeutic probiotics with an appropriate prebiotic energy source has been referred to as “synbiotics” [9]. As the term implies, synbiotics may improve survival of probiotics in the GI tract to synergistically enhance their benefits [10]. A study in ulcerative colitis patients showed that a synbiotic treatment improved quality-of-life assessments to a greater extent than the probiotic or prebiotic alone [11]. However, other human trials examining synbiotic effects on GI health did not perform statistically better than placebo or standard-of-care in individuals with IBS or infected with Helicobacter pylori, respectively [12], [13]. This lack of effect may be due to mismatched combinations of pre and probiotics. In the current study, we examined the synbiotic effects of Bifidobacterium lactis BL04 and the phage mixture, PreforPro. We selected this combination because our previous data showed that PreforPro increased commensal Bifidobacterium [8]. In a 4-week, randomized, double-blind, placebo-controlled trial, we examined the effects of A) a maltodextrin placebo, B) B. lactis BL04 alone, or C) B. lactis BL04 + PreforPro, on the gut microbiota...
and various parameters of GI health. Specifically, our primary outcome measures included a digestive health questionnaire, stool consistency measurements, and molecular analysis of the gut microbiota. We hypothesized that synbiotic consumption (B. lactis BL04 + PreforPro) would improve one or more aspects of digestive health and stool consistency in our participant population compared to the probiotic alone.

2. Materials and Methods

A. Study design

The BacterioPHAGE for Gastrointestinal Health 2 Study (PHAGE-2 Study) is a 4-week, randomized, parallel-arm, double-blind, placebo-controlled clinical intervention trial. The PHAGE 2 Study was designed to test whether combining supplemental bacteriophages with a probiotic would provide additional benefits to GI health and gut microbiota compared to consuming a probiotic alone. The Colorado State University Institutional Review Board approved the study protocol (CSU #19-9145H) and all participants provided written informed consent.

Participants were pre-qualified by phone screening and attended an in-person study visit at Colorado State University’s Food and Nutrition Clinical Research Laboratory (FNCRL) in the Department of Food Science and Human Nutrition. Participants were fasted at least 8 hours and asked to abstain from exercise for at least 12 hours prior to clinic visits. They were also instructed to refrain from taking any medications or dietary supplements for 24 hours prior to their visits. During their initial visit (baseline), eligibility was confirmed by taking anthropometric measurements of height (cm) and weight (kg) to calculate BMI and completing a written medical health questionnaire to determine medical history and current medication use. At both baseline and 4-week (final) visits, participants were asked to complete a digestive health questionnaire, undergo several measures of cardiovascular function (reported in Trotter et al. 2020 in press), and provide a venous blood and stool sample. They were also provided with a stool log and asked to keep a daily record of their bowel movements.

After undergoing sample collections and analysis procedures at the baseline visit, participants were randomly assigned to 1 of 3 treatments groups: (A) 15 mg rice maltodextrin (placebo); (B) 1x10^9 Bifidobacterium animalis subspecies lactis strain BL04 (B. lactis BL04); or (C) 1x10^9 B. lactis BL04 + 1x 10^6 LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae bacteriophages, marketed as PreforPro (B. lactis BL04+PreforPro). Participants were asked to consume one 15-mg capsule per day during the 4-week intervention period. All treatment capsules contained maltodextrin from rice and medium chain triglycerides from palm and coconut oil as a filler material. Participants were randomized to treatment groups using the second generator at www.randomization.com. To assess treatment compliance, participants returned all unused treatment capsules at their final visit.

Participants were asked to maintain their normal eating and exercise habits throughout the course of the study. To aid in determining dietary compliance, participants were completed a 2-day diet record at the beginning and end of the treatment period, including 1 weekday and 1 weekend day, using the National Institutes of Health, National Cancer Institute Automated Self-Administered 24-hour dietary assessment tool (ASA24; https://asa24.nci.nih.gov). For each of the 2-day diet records,
participants recorded all foods, drinks, and supplements they consumed in a 24-hour period and the time of day they were eating and drinking.

B. Participant characteristics

Healthy, adult participants were recruited from Fort Collins, Colorado and surrounding areas by referral from local healthcare practitioners, flyers, email, and through word of mouth. Initial eligibility was determined by a phone screening questionnaire and confirmed onsite at the FNCRL via interview and BMI assessment by the clinical coordinator. Inclusion and exclusion criteria are presented in Table 1. Participants were asked to maintain their regular diet and exercise habits as well as to limit alcohol consumption to 1-2 drinks per day or no more than 8 drinks per week during the study. They were also asked to abstain from taking any supplemental pre- or probiotics. A summary of baseline participant characteristics can be found in Table 2.

Table 1. Participant Inclusion and Exclusion Criteria

| Inclusion Criteria | Exclusion Criteria |
|--------------------|--------------------|
| Men and women      | Pregnant and breastfeeding women |
| Aged 18-65 years   | Taking medication that would influence the endpoints of the study (statins, metformin, nonsteroidal anti-inflammatory drugs, monoamine oxidase inhibitors, blood pressure medications) and taking probiotics and/or botanical supplements that target the GI tract or gut microbiota. |
| Normal, overweight, or class 1 obese (BMI 20 – 34.9 kg/m²) | Current diagnosis of cancer, liver or kidney disease, gastrointestinal diseases, and metabolic disorders. |

Table 2. Participant Baseline Characteristics

| Treatment               | Male (n) | Female (n) | Height (cm) | Weight (kg) | BMI | Age       |
|-------------------------|----------|------------|-------------|-------------|-----|-----------|
| Placebo                 | 8        | 13         | 169.9 ± 8.2 | 71.3 ± 10.6 | 24.67 ± 2.8 | 36.5 ± 13.0 |
| B. lactis BL04          | 10       | 13         | 169.9 ± 8.2 | 71.5 ± 10.7 | 24.7 ± 2.8  | 36.5 ± 13.2  |
| B. lactis BL04 + PreforPro | 7       | 15         | 170.1 ± 8.22| 71.6 ± 10.4 | 24.7 ± 2.71 | 36.1 ± 13.3 |

Data represent mean ± SD.

C. Comprehensive metabolic panels

Blood samples (100 ul) were collected from the antecubital vein in a lithium heparin tube and immediately analyzed using a Piccolo Metlyte Plus CRP Reagent Disc, which included glucose, blood urea nitrogen (BUN), creatinine (CRE), creatinine kinase (CK), Na+, K+, Cl- and C-reactive protein (CRP), on the Piccolo Xpress Chemistry Blood Analyzer (Abaxis, Union City, CA, USA).

D. Digestive health and bowel movement assessment

Participants completed a digestive health questionnaire at baseline and after 4 weeks on treatment to assess perceived effects on GI symptoms, as previously described [14]. Briefly, the
questionnaire had 4 sections corresponding to gastric function, GI inflammation, small intestine (SI) and pancreas pain, and colon function. Participants ranked questions within each section, choosing no/rarely, occasionally, often, or frequently. Symptom severity was then ranked according to their priority status outlined in Table 3. The percentage of participants that experienced low, moderate, and high priority gastrointestinal symptoms at the initial and follow-up visit were calculated. Initial test scores (baseline) and retest scores (week 4) were compared within treatment groups across sections of the questionnaire to assess the percentage of participants that experienced an improvement, worsening, or no change to the severity of their gastrointestinal symptoms after the 4-week intervention.

| Table 3. Priority Status Based on Scores from the Digestive Health Questionnaire |
|---------------------------------------------------------------|
| **Symptom Severity** | **Questionnaire Section** | **Gastric Function** | **GI Inflammation** | **SI & Pancreas** | **Colon** |
|----------------------|--------------------------|----------------------|---------------------|------------------|-----------|
| Low                  |                          | 1-4                  | 1-4                 | 2-8              | 2-8       |
| Moderate             |                          | 5-8                  | 5-8                 | 9-16             | 9-16      |
| High                 |                          | 9-56                 | 9-72                | 17-80            | 17-72     |

**Abbreviations:** GI, gastrointestinal; SI, small intestine.

Participants were also asked to record all bowel movements during the study and rank them according to the Bristol Stool chart. Participants were given a copy of the Bristol Stool Chart as a reference to help determine stool type. Types included Type 1 (separate hard lumps), Type 2 (lumpy and sausage like), Type 3 (a sausage shape with cracks in the surface), Type 4 (like a smooth, soft sausage or snake), Type 5 (soft blobs with clear-cut edges), Type 6 (mushy consistency with ragged edges) and Type 7 (liquid consistency with no solid pieces). For data analysis, each stool type was coded as either hard (Types 1 or 2), soft (Types 3, 4, or 5), or diarrhea (Type 6 or 7). Stools categorized as soft were considered normal, while hard and diarrhea stools were considered abnormal.

### E. Stool sample processing

Stool samples were collected at home, stored refrigerated, and brought into the clinic within 24 hours. In the clinic, they were stored at 4°C and processed within 24 hours in the following manner: two sterile cotton swabs were inserted into the stool at three separate locations and then stored at -80°C for DNA extraction. Approximately 1 g of stool was mixed with PBS buffer containing 10% glycerol and stored at -80°C prior to use for phage counts. Remaining stool was transferred to a 100 ml sterile plastic container and stored at -80°C for possible future analyses.

### F. Phage enumeration

Fecal samples stored in glycerol were thawed at room temperature. Samples were vortexed for 5 min with ceramic beads in 1 mL 2x sodium chloride magnesium sulfide (SM) buffer to homogenize [15]. A 1.5 mL aliquot was removed and centrifuged at 2000 g for 2 min, and supernatant was removed and centrifuged again at 140,000 rpm for 10 minutes. 500 ul of prepared sample was mixed with 100 ul of *E. coli* K12 culture (grown overnight in Luria Bertani (LB) broth on a 37°C shaker to OD<sub>600</sub>=0.7-1.0) and incubated at 37°C for 5 min. 3 mL of freshly prepared LB soft agar was then added...
to the mixture and immediately poured on LB agar plates which were pre-warmed to 37°C for 30 minutes. Each sample was plated in duplicate and quantified using plated phage standard dilution plates.

**G. Microbiota Assessment**

Fecal DNA was extracted using the FastDNA® Kit (MP Biomedicals, #116540400) following manufacturer’s protocol. The V4 region of the 16S rRNA gene was amplified following the Earth Microbiome Project protocol using the 515F-806R primer set [16] containing a unique 12bp error correcting barcode included on the forward primer. Cycling and sequencing conditions were as previously described [17]. DNA extraction controls, no template PCR controls, and the Zymo mock community were included on each sequencing plate. Sequence reads were imported into QIIME2 version 2020.2 for analysis [18]. Briefly, the sequence reads were demultiplexed, and concatenated. Utilizing a Phred score cutoff of 30, upon examining the demultiplexed data the reverse reads did not meet the quality filtering parameter. As such analysis proceeded with single-end sequences which were trimmed to 209 base pairs based on the same quality score. Reads were binned into ASVs using the DADA2 pipeline [19]. Taxonomic assignments were made using GreenGenes version 13.8. Samples with low reads or suspected contamination were removed and mitochondrial and chloroplast sequences were filtered from remaining samples. The resulting feature tables and taxonomy files were imported into MyPhyloDB version v.1.2.0 [20]. Alpha-diversity was calculated using Faith’s and Shannon metrics through the QIIME2 diversity plugin. Beta diversity was determined by Bray Curtis distance measurements and visualized by PCoA in MyPhyloDB. Differences in taxa among treatments were assessed in MyPhyloDB using univariate ANCoVA and multivariate DiffAbund.

**H. Statistical analysis**

Statistical analysis of clinical parameters (GI questionnaires, stool logs, metabolic panel analytes, dietary intakes, anthropometrics) and qPCR data was completed using GraphPad Prism, version 8.3.0. All data were analyzed using a 2-way mixed model ANOVA with Sidak’s post hoc for multiple comparisons. In addition, baseline adjusted final values were analyzed using a 1-way ANOVA with Tukey’s post hoc for multiple comparisons. Statistical significance was assigned as p<0.05 and a statistical trend was defined as between p>0.10-0.05. Microbiota alpha-diversity parameters were analyzed using a one-way ANOVA with a non-parametric Kruskil-Wallis post hoc test, and β-diversity was analyzed by PERMANOVA with 1000 iterations. Analysis of Covariance (ANCoVA) with Tukey’s post-hoc for multiple comparisons and a negative binomial general linear model [21] were used to determine statistically different taxa between time points and treatment groups.

### 3. Results

#### 3.1 Participant characteristics

A total of 153 individuals were screened for eligibility. From this sample, 93 were eligible and enrolled in the study. Among these, 25 participants were enrolled in a different RCT with the same inclusion and exclusion protocol (Trotter et al., 2020- in press). Of the 68 enrolled in this branch of the study, 2 dropped after visit 1. A total of 66 individuals who met all the inclusion and exclusion criteria
completed this 4-week, randomized, parallel-arm, double-blind, placebo-controlled clinical trial (Figure 1).

**Figure 1:** Consort flow diagram of participants through study enrollment to completion

Approximately 12% of participants involved in the study experienced adverse events, with the severity of reported adverse events either mild or moderate. No adverse events were reported as severe or life threatening, suggesting that there was a low risk associated with both treatments, and no participants dropped out of the study due to adverse events. The *B. lactis* BL04 treatment group experienced the highest incidence of adverse events, accounting for about 7.5% of the total reported study-related events. Major treatment-associated adverse events included constipation, bloating, flatulence, fatigue/lack of energy, or other.

### 3.2 Study compliance

Overall compliance with the treatment protocol was about 95% with individual compliance ranging from 73-100%. Under the intention-to-treat analysis principle, all individual data were analyzed, regardless of compliance. Within treatment groups compliance was as follows: Placebo: average compliance=97%, compliance range=77-100%; *B. lactis* BL04: average compliance=95%, compliance range=80-100%; *B. lactis* BL04 + PreforPro: average compliance=95%, compliance range=73-100%.

The overall number of participants that completed the self-reported 24-hour food recalls was low, with only about 53% of participants completing two dietary records at both baseline and during the 4-week intervention. Within each of the treatment groups, dietary compliance for completing the food recall was as follows: Placebo: average compliance=48%, *B. lactis* BL04: average compliance=58%, *B. lactis* BL04 + PreforPro: average compliance=57%. From the dietary information collected, there were no significant differences in total calories, macronutrients, fiber, cholesterol, or saturated fat consumed over the course of the study within or between any of the treatment groups (Table 4). Finally, variability among and within treatment groups had no influence on body weight.
during the study as the average BMI was about 24 kg/m² (see Table 1) for all groups both pre- and post-treatment and average weights fluctuated by <1 kg in each treatment group. Likewise, average values for analytes measured by the Metlyte plus CRP Reagent Disk did not vary significantly across groups or pre- to post-treatment within groups and all values remained within clinically normal ranges throughout the study (Supplemental Table 1).

### Table 4. Self-Reported Dietary Intake

|                      | Placebo (n=10) | B. lactis BL04 (n=14) | B. lactis BL04 + PreforPro (n=12) |
|----------------------|---------------|-----------------------|-----------------------------------|
|                      | Baseline      | Final                 | Baseline                          | Final                 | Baseline                        | Final                 |
| Energy (KCAL)        | 2269 ± 999    | 2089 ± 982            | 1775 ± 735                        | 1853 ± 675            | 1739 ± 474                      | 1905 ± 719            |
| PRO (g)              | 99 ± 50       | 96 ± 50               | 85 ± 49                           | 74 ± 29               | 70 ± 18                         | 68 ± 27               |
| TFAT (g)             | 103 ± 56      | 86 ± 42               | 73 ± 27                           | 84 ± 44               | 66 ± 30                         | 73 ± 29               |
| SFAT (g)             | 33 ± 18       | 27 ± 14               | 21 ± 9                            | 29 ± 21               | 19 ± 6                          | 23 ± 12               |
| CHOL (mg)            | 358 ± 259     | 324 ± 271             | 282 ± 299                         | 277 ± 281             | 215 ± 101                       | 180 ± 129             |
| CARB (g)             | 240 ± 104     | 225 ± 118             | 194 ± 103                         | 199 ± 91              | 209 ± 54                        | 222 ± 71              |
| FIBER (g)            | 25 ± 11       | 22 ± 12               | 27 ± 19                           | 23 ± 16               | 26 ± 21                         | 24 ± 14               |

Data represent mean ± SD. No values were statistically significant with a p-value < 0.05. Abbreviations: PRO (protein), TFAT (total fat), SFAT (saturated fat), CHOL (cholesterol), CARB (carbohydrates)

### 3.3 GI health and digestion

Total point scores for each section of the digestive health questionnaire represent symptom severity related to gastric function, GI inflammation, small intestine and pancreas pain, and colon pain. Changes in individual scores, for each section, pre- to post-treatment are shown in Supplemental Figure 1. There was a significant main effect for Time (p=0.004) and average scores from the gastric function section of the questionnaire were significantly reduced (improved) with B. lactis BL04 treatment (Figure 2a; p= 0.046; [CI: -2.851 to -0.019]); although there were no significant changes in gastric function noted within the placebo or the PreforPro + B. lactis BL04 group or among any of the treatments. There was also a significant main effect for time (p=0.005) in perceived improvement in GI inflammation and a significant reduction in the average symptom severity with the B. lactis BL04 + PreforPro treatment (Figure 2b; p= 0.005; [CI: -3.509 to -0.307]). While there were no other statistically significant differences observed, there was also a trend for improved colon pain in individuals on the B. lactis BL04 + PreforPro treatment (Figure 2d; p=0.082; [CI: -5.802 to 0.2568]). Notably, while there were no other significant improvements, there were also no significant worsening of symptoms, indicating that both treatments, at the levels administered, were tolerable.
**Figure 2.** Average symptom severity before and after treatment as determined by GI Questionnaire

When comparing baseline adjusted (final-baseline) means among groups, there were no significant differences (Supplemental Figure 2). However, there was a small positive effect, determined using Cohen’s $d$, in symptom severity for the GI Inflammation and colon pain sections with *B. lactis* BL04 + PreforPro when compared to the placebo, while the effect of *B. lactis* alone was negligible (Table 5; [22]).

|                      | Gastric Function | GI Inflammation | SI and Pancreas Pain | Colon Pain |
|----------------------|------------------|-----------------|----------------------|------------|
| *B. lactis* BL04     | 0.05             | -0.13           | -0.17                | -0.14      |
| *B. lactis* BL04 +   | -0.38            | 0.30            | 0.11                 | 0.45       |
| PreforPro            |                  |                 |                      |            |

The GI health questionnaire scores corresponded to priority levels of mild (0-24 total points), moderate (25-48 total points), or severe (49-280 total points) symptoms in each of the target areas. Using these priority scores, we were able to calculate whether participants’ symptoms qualitatively worsened, improved, or stayed the same during the study (Figure 3). Regardless of treatment group, most participants experienced no change in the overall priority level of their perceived GI distress. Only a small percentage of participants experienced an overall worsening of priority status from baseline to follow-up, with the lowest percentage of participants in the Placebo group (2%) and the highest percentage in the *B. lactis* group (8%) moving from a lower to a higher priority score. The PreforPro + *B. lactis* group saw the greatest percentage (24%) of participants with overall
improvements in the priority status of their symptoms (ie. moved from a higher to a lower priority ranking). In comparison, only 15% of participants on *B. lactis* alone moved to a lower priority score after treatment.

**Figure 3.** Priority Changes in Overall Digestive Symptoms from Baseline to Follow-up

![Priority Changes in Overall Digestive Symptoms from Baseline to Follow-up](image)

The percentage of persons whose ratio of normal (Bristol Type 3, 4 or soft stool) to abnormal stool (Bristol Type 1, 2, 5, 6 or hard or watery stool) that improved, declined, or stayed the same is shown in Table 6. A decline in stool consistency was defined as having a higher proportion of bowel movements that were considered abnormal (hard or diarrhea) to stool that was normal (soft). The majority of participants experienced no change in stool consistency from week 1 to week 4. However, a substantial percentage of participants in the *B. lactis* BL04 (22%) and *B. lactis* BL04 + PreforPro (32%) groups experienced a decline in stool consistency from week 1 to week 4. Almost half of those in the *B. lactis* BL04 + PreforPro group saw no change in stool consistency from baseline to follow-up (41%) while the *B. lactis* BL04 group saw the greatest improvement in stool consistency over time (39%).

Because participants began taking their respective treatments concurrent with recording bowel movements, there may have been rapid changes in stool consistency that occurred within the first week of treatment, obscuring treatment effects. Therefore, we also calculated changes in stool consistency using only the first two recorded days compared to the reported stool consistency at week 4. We saw higher percentages of participants reporting improved stool consistency in both the Placebo and *B. lactis* BL04 groups (33% and 52%, respectively). Most participants in the *B. lactis* BL04 + PreforPro group had a decline in stool consistency (59%) from baseline to follow-up. There was also a noticeable negative placebo effect with 48% of participants reporting a decline in stool consistency in the Placebo group.

**Table 6: Stool consistency changes from baseline to follow-up visit**

|                      | Stool changes between Week 1 and Week 4 | Stool changes between Days 1 and 2 and Week 4 |
|----------------------|----------------------------------------|---------------------------------------------|
|                      | Improved | Declined | Same | Improved | Declined | Same |
| Placebo              | 29%      | 33%      | 38%  | 33%      | 48%      | 19%  |
| *B. lactis* BL04     | 39%      | 22%      | 39%  | 52%      | 39%      | 9%   |
| *B. lactis* BL04 + PreforPro | 27%   | 32%      | 41%  | 27%      | 59%      | 14%  |

No values were found to be statistically different.
3.4 Microbiota changes

Phage plating was conducted to confirm the presence of viable *E. coli*-targeting phages in stool samples. No phages were detected in baseline samples from any treatment group or from the 4-week samples collected from individuals in the Placebo or the *B. lactis* BL04 groups. About 44% of the final samples collected from individuals assigned to the *B. lactis* BL04 + PreforPro group had viable phages detected, although the total number recovered varied from 7-30,531 pfu/gram with the average being 5,103 pfu/gram.

Using 16s rRNA amplicon sequencing, we assessed whether the three treatments impacted the gut microbial community. The microbiota in all samples was primarily represented by the phyla Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, and Verrucomicrobiota and the proportion of these phyla did not significantly differ between groups or over time. The alpha-diversity metrics for Faith’s Phylogenetic Diversity (Faith’s PD), Shannon’s diversity, and Pielou’s Evenness did not significantly differ between treatment groups or within any treatment group over time. (Supplemental Table 2). Likewise, examining β-diversity using Bray-Curtis distances visualized by PCoA with Non-Metric Dimensional Scaling (NMDS) revealed no significant clustering by treatment, as determined by PERMANOVA (Figure 4).

**Figure 4.** PCoA of Bray-Curtis distances at baseline and final visit for each treatment group.

![PCoA of Bray-Curtis distances](image)

Although no changes were observed in the overall composition and diversity of the microbiota, some select taxa were significantly increased or decreased in the two probiotic treatment groups, but not in the Placebo. Using the DiffAbund function in MyPhylodb, we saw some changes in specific taxa. Figure 5 shows the baseline to final visit changes within each treatment group with the blue bars representing log fold-change (FC) and the orange bars representing the log count per million (CPM). Within the Placebo group, there were decreases in *Pseudomonas* and *Coprobacillus* and increases in *Aggregatibacter* and *Ruminococcus*. This increase in *Ruminococcus* (*gnavus*) was also observed using a less sensitive parametric ANCoVA analysis (p=0.04). Most notably, *Lachnobacterium* and *Lactobacillus* increases were noted with both *B. lactis* treatment groups; however, the increase in *Lachnobacterium* was approximately equal between these groups while there was a ~3-logFC greater increase in *Lactobacillus* observed in *B. lactis* BL04 + PreforPro compared to the probiotic alone. *Prevotella* was concurrently decreased with both treatments, although the *B. lactis* BL04 + PreforPro showed a slightly greater decrease. Finally, opposing changes in *Catenibacterium* and *Desulfovibrio* were observed between these treatment groups. With regard to the potential “prebiotic” effects of PreforPro, we saw increases in *Atopobium*, *Gardnerella/Bifidobacterium*, *Clostridium*, and *Lactobacillus*, which are all reportedly responsive to traditional fiber-based prebiotics [23]. The increase in *Clostridium* (*citroniae*) was also observed in this treatment group when analyzing with ANCoVA (p=0.03). Finally, there were also decreases in *Citrobacter* and *Desulfovibrio*, which are often associated with increased gut inflammation and GI disorders [24], [25].
Figure 5. Changes in specific taxa within treatment groups, identified using a genewise negative binomial GLM approach.

Additionally, we queried our sequence data for reads that matched *E. coli* in BLASTn to determine whether phage consumption. We found several ASV’s that matched *E. coli*, but which could not be confirmed because of a high degree of homology in the sequenced region, resulting in equal matches with several closely related taxa. However, an assessment of these putative *E. coli* reads revealed a trending decrease (ANCoVA; p=0.094) from baseline to the final visit with *B. lactis* BL04 + PreforPro, which was not observed in the other treatment groups (Supplemental Figure 3).

4. Discussion

There is growing interest in the incorporation of phages with probiotic dietary supplements. Phages can target specific pro-inflammatory or pathogenic organisms in the gut and potentially enhance the GI benefits of the probiotics, although evidence for these effects in human trials is currently lacking. In this randomized, double-blind, placebo-controlled clinical study we observed the effects of *B. lactis* BL04, with or without the *E. coli*-targeting phage mixture marketed as PreforPro, on gastrointestinal well-being and modulation of the gut microbiota. The beneficial effect of supplementation with *B. lactis* BL04 appeared restricted to improvements in symptoms related to gastric function and stool consistency in 52% of participants. Participants who consumed *B. lactis* BL04 + PreforPro showed improvements in digestive symptoms related to GI inflammation and colon...
pain and had the highest percentage of individuals reporting overall reduced symptom severity. This is largely in agreement with a previous study, where Ginden et al. reported that PreforPro alone resulted in an improvement in gastric function and colon pain, but likewise reported a placebo effect [14]. Additionally, in the population of phage-only consuming participants, a higher percentage of participants reported an overall worsening in symptoms than was reported in the current study. This indicates that there might be some additive benefit to consuming these phages with a probiotic. However, the probiotic used in this study, B. lactis BL04 alone, elicited minimal effects on our study population, which was largely healthy adults with no diagnosed GI diseases. Bifidobacterium lactis BL04 is often studied in conjunction with other probiotic strains, and a recent study suggested that a five-strain mixture, containing B. lactis BL04, improved symptoms of antibiotic-associated diarrhea when given at a high dose (>10^{10} CFU) [26]. Our study used a single strain, lower dose (10^9 CFU), and tested on a healthy population. While most people occasionally experience GI distress or irregular bowel movements, it is likely the effects of this probiotic are more subtle in healthy individuals. It would be interesting to determine whether the benefits we observed are more pronounced with a combination probiotic and/or in patients with GI disorders.

Consistent with other published phage literature, the combination of B. lactis BL04 + PreforPro did not significantly impact gut ecology, with no significant shifts in either alpha- or beta-diversity parameters or large phyla-level changes in taxa. This concurs with our previous study, which looked at impacts of the phages alone on gut microbiota [8]. Similarly, E. coli-targeting phages added to a simulated gut environment with a defined microbial consortium only showed effects on the target species and did not disrupt commensal organisms [27]. However, various lytic phages administered to gnotobiotic mice transplanted with a defined human commensal microbiota did demonstrate cascading effects on many of the non-target species, likely mediated by complex ecological interactions between bacteria [28]. This consortium was made up of only 10 bacterial species, suggesting that effects on these species may have been more profound than if they were observed within the context of an intact human gut containing hundreds of bacterial species.

Despite a lack of global alterations in the microbiota, the treatments were associated with changes in a small number of taxa. Most notably, we saw an increase in taxa identified as Lactobacillus after 4-weeks of both B. lactis BL04 and B. lactis BL04 + PreforPro. However, the increase was 10-fold greater than baseline levels when phages were included in the B. lactis treatment compared to a ~4-fold increase seen with the probiotic alone. Oral administration of a lytic phage induced similar increases in Lactobacillus in a mouse model, as well as increasing Bifidobacterium [29]. It is interesting to note that we did not observe increased Bifidobacterium in either treatment group, despite daily consumption of 10^9 CFU of B. lactis BL04. A similar finding was reported in a study of healthy volunteers taking Amoxicillin and a multi-species probiotic, which included B. lactis, E. faecalis and several other Bifidobacteria and Lactobacilli. Using culture-based methods, the investigators only reported an increase in stool Enterococci [30]. We used a sequencing approach, which is not sufficiently sensitive to distinguish bacteria at the species level and it is possible that the baseline levels of Bifidobacterium across our treatment groups were sufficiently high to obscure any treatment effects. Finally, there were several taxa that have demonstrated inflammatory effects on the gut that were reduced after treatment of B. lactis BL04 + PreforPro. Specifically, there were decreases in Citrobacter and Desulfovibrio. Citrobacter overgrowth is associated with bloating, and both Faber et al. [31] and Gangi et al. [24] reported increased levels of Citrobacter in IBS patients. In the Faber study,
symptoms of bloating and abdominal pain were alleviated after reducing *Citrobacter*, and other pro-inflammatory bacteria and yeasts, by antibiotic treatment and supplementation with probiotics [31]. *Desulfovibrio* is a sulfate-reducing bacteria that is also often associated with IBS [25] and induces alterations in colonic architecture, cellular infiltration into the lamina propria, and increased inflammatory immune responses in mouse models of colitis [32]. Therefore, reduction of these bacteria may have been responsible for the symptom reduction reported in our participant population and suggest that future trials in a population with IBS or colitis may be warranted.

The study has some strengths and limitations worth considering. One major strength is that this study is a randomized, double-blind, placebo-controlled clinical trial. Randomized controlled trials are the gold standard for study design since they eliminate much inherent bias that other study designs introduce. Similarly, compliance across treatments was high at about 95% with no significant dietary differences in total calories, macronutrients, fiber, cholesterol, or saturated fat within any of the treatment groups. However, we recognize that there are several limitations in this study. First, true baseline data is lacking for stool consistency as measurements were not taken before the start of the intervention began, but rather the same day that participants came to the FNCRL for their initial visit. To minimize this affect, we analyzed Day 1 and 2 as a baseline in comparison to Week 4 in addition to analyzing the Week 1 and Week 4 comparisons. Another limitation is that participants had the option of numerically assessing their stool using the Bristol Stool Chart or provide a designation of hard (H), soft (S), or diarrhea (D). This mixture in data capture methods prevented quantitative assessment of stool changes, although it was still useful for functional assessment. Finally, high participant burden of recording every bowel movement for a month could have led to participants not recording all of their stools or recording only their first bowel movement of the day.

In conclusion, the present study demonstrates that oral supplementation of *B. lactis* BL04 over the course of 4 weeks has the potential to improve stool consistency, and *B. lactis* BL04 with PreforPro can significantly improve some GI symptoms. In addition, a lack of global changes to the microbiota in combination with specific modulation of certain taxa, like *Lactobacillus*, suggest that PreforPro displays prebiotic-like effects and may potentiate microbiota changes associated with the intake of the *B. lactis* BL04 probiotic. While we did not observe significant improvements in all aspects of GI well-being or stool consistency, the findings of this study indicate low risk for oral supplementation with phages and suggests that probiotic with prebiotic phage cocktails may offer a safe solution for management of GI symptoms in healthy adults.

**Supplementary Materials:** Figure S1: Individual scores at baseline and post-treatment for each of the 4 sections of the gastrointestinal health questionnaire. Figure S2: Baseline adjusted scores for each section of the gastrointestinal health questionnaire across treatments. Figure S3: Abundance of unclassified Enterobacteriaceae that putatively belong to *Escherichia coli*. Table S1: Metabolic parameters in blood before and after treatment for each group. Table S2: Alpha Diversity Metrics

**Author Contributions:** “Conceptualization, T.L.W., T.C.W. and S.A.J.; methodology, T.L.W.; data curation, D.S.G., K.E.F., S.D.W., R.E.T., A.R.V., S.A.J; formal analysis, D.S.G., S.D.W., Y.W., K.E.F., and T.L.W.; investigation, D.S.G, K.E.F., A.R.V., and R.E.T.; writing—original draft preparation, D.S.G. and T.L.W.; writing—review and editing, all authors; funding acquisition, T.L.W and S.A.J. All authors have read and agreed to the published version of the manuscript.”

**Funding:** This research was funded by Deerland Enzymes (Kennesaw, GA).
Acknowledgments: We would like to acknowledge the students and staff who worked in the FNCRL for always stepping in to help with blood collection and assisted with REDCap, especially Dr. Nicole Litwin, Ms. Kiri Michell, and Ms. Lauren Grabos. We’d also like to thank Dr. John Deaton and Ms. Anamaria Cuentas for training on phage isolation procedures and Mr. Michael Lelko for providing research strains and for technical information on the *B. lactis* and PreforPro capsule preparations.

Conflicts of Interest: The authors declare no conflict of interest. The funders (Deerland Enzymes; Kennesaw, GA) provided type organisms (*B. lactis*, *E. coli*, phage mixture), and protocols for phage counts. They also approved the design of the study and agreed to publication of the data but had no role in the initial design of the study; in the collection, analyses, or interpretation of data; or in the writing of the manuscript.

References

[1] M. E. Sanders, A. Benson, S. Lebeer, D. J. Merenstein, and T. R. Klaenhammer, “Shared mechanisms among probiotic taxa: implications for general probiotic claims,” *Current Opinion in Biotechnology*, vol. 49. Elsevier Ltd, pp. 207–216, Feb. 01, 2018, doi: 10.1016/j.copbio.2017.09.007.

[2] B. R. Goldin and S. L. Gorbach, “Clinical Indications for Probiotics: An Overview,” *Clinical Infectious Diseases*, vol. 46, no. s2, pp. S96–S100, Feb. 2008, doi: 10.1086/523333.

[3] M. L. Ritchie and T. N. Romanuk, “A Meta-Analysis of Probiotic Efficacy for Gastrointestinal Diseases,” *PLoS ONE*, vol. 7, no. 4, p. e34938, Apr. 2012, doi: 10.1371/journal.pone.0034938.

[4] C. Zhang et al., “Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults,” *Clinical Nutrition*, vol. 0, no. 0, 2020, doi: 10.1016/j.clnu.2020.01.005.

[5] A. P. S. Hungin et al., “Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice - An evidence-based international guide,” *Alimentary Pharmacology and Therapeutics*, vol. 38, no. 8. John Wiley & Sons, Ltd, pp. 864–886, Oct. 01, 2013, doi: 10.1111/apt.12460.

[6] G. R. GIbSON and M. B. ROBERFROID, “Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics,” *The Journal of nutrition*, vol. 125, no. 6, 1995, Accessed: Jul. 08, 2020. [Online].

[7] G. R. Gibson et al., “Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics,” *Nature Reviews Gastroenterology and Hepatology*, vol. 14, no. 8. Nature Publishing Group, pp. 491–502, Aug. 01, 2017, doi: 10.1038/nrgastro.2017.75.

[8] H. P. Febvre et al., “PHAGE study: Effects of supplemental bacteriophage intake on inflammation and gut microbiota in healthy adults,” *Nutrients*, vol. 11, no. 3, Mar. 2019, doi: 10.3390/nu11030666.

[9] K. R. Pandey, S. R. Naik, and B. v. Vakil, “Probiotics, prebiotics and synbiotics- a review,” *Journal of Food Science and Technology*, vol. 52, no. 12. Springer India, pp. 7577–7587, Dec. 01, 2015, doi: 10.1007/s13197-015-1921-1.

[10] A. Cenic and W. Chingwaru, “The role of functional foods, nutraceuticals, and food supplements in intestinal health,” *Nutrients*, vol. 2, no. 6. MDPI AG, pp. 611–625, 2010, doi: 10.3390/nu2060611.

[11] S. Fujimori et al., “A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis,” *Nutrition*, vol. 25, no. 5, pp. 520–525, May 2009, doi: 10.1016/j.nut.2008.11.017.

[12] A. Šmid, L. Stmiša, K. Bajc, D. Vujíc-Podlipec, B. Bogovič Matijašić, and I. Rogelj, “Randomized clinical trial: The effect of fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium BB-12® and Beneo dietary fibres on health-related quality of life and the symptoms of
irritable bowel syndrome in adults,” *Journal of Functional Foods*, vol. 24, pp. 549–557, Jun. 2016, doi: 10.1016/j.jff.2016.04.031.

[13] G. Handan Ustundag, H. Altuntas, Y. Dilek Soysal, and F. Kokturk, “Clinical Study The Effects of Synbiotic (Bifidobacterium lactis B94 plus Inulin) Addition on Standard Triple Therapy of Helicobacter pylori Eradication in Children,” 2017, doi: 10.1155/2017/8130596.

[14] M. Gindin, H. P. Febvre, S. Rao, T. C. Wallace, and T. L. Weir, “Bacteriophage for Gastrointestinal Health (PHAGE) Study: Evaluating the Safety and Tolerability of Supplemental Bacteriophage Consumption,” *Journal of the American College of Nutrition*, vol. 38, no. 1, pp. 68–75, Jan. 2019, doi: 10.1080/07315724.2018.1483783.

[15] J. L. Castro-Mejía et al., “Optimizing protocols for extraction of bacteriophages prior to metagenomic analyses of phage communities in the human gut,” *Microbiome*, vol. 3, no. 1, p. 64, Nov. 2015, doi: 10.1186/s40168-015-0131-4.

[16] J. G. Caporaso et al., “Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms,” *ISME Journal*, vol. 6, no. 8, pp. 1621–1624, Aug. 2012, doi: 10.1038/ismej.2012.8.

[17] D. M. Lee et al., “Microbial Metabolite Indole-3-Propionic Acid Supplementation Does Not Protect Mice from the Cardiometabolic Consequences of a Western Diet,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, May 2020, doi: 10.1152/ajpgi.00375.2019.

[18] E. Bolyen et al., “Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2,” *Nature Biotechnology*, vol. 37, no. 8. Nature Publishing Group, pp. 852–857, Aug. 01, 2019, doi: 10.1038/s41587-019-0209-9.

[19] B. J. Callahan, P. J. McMurdie, M. J. Rosen, A. W. Han, A. J. A. Johnson, and S. P. Holmes, “DADA2: High-resolution sample inference from Illumina amplicon data,” *Nature Methods*, vol. 13, no. 7, pp. 581–583, Jun. 2016, doi: 10.1038/nmeth.3869.

[20] D. K. Manter, M. Korsa, C. Tebbe, and J. A. Delgado, “myPhyloDB: a local web server for the storage and analysis of metagenomic data,” *Database*, vol. 2016, p. 39, 2016, doi: 10.1093/database/baw039.

[21] Y. Chen, D. McCarthy, M. Ritchie, M. Robinson, G. Smyth, and E. Hall, “edgeR: differential analysis of sequence read count data User’s Guide.” Accessed: Jul. 08, 2020. [Online].

[22] J. Cohen, “Statistical Power Analysis for the Behavioral Sciences Second Edition.” Accessed: Jul. 08, 2020. [Online].

[23] P. C. Vinke, S. el Aidy, and G. van Dijk, “The Role of Supplemental Complex Dietary Carbohydrates and Gut Microbiota in Promoting Cardiometabolic and Immunological Health in Obesity: Lessons from Healthy Non-Obese Individuals,” *Frontiers in Nutrition*, vol. 4. Frontiers Media S.A., p. 34, Jul. 24, 2017, doi: 10.3389/fnut.2017.00034.

[24] L. Ganji et al., “Dysbiosis of fecal microbiota and high frequency of Citrobacter, Klebsiella spp., and Actinomyces in patients with irritable bowel syndrome and gastroenteritis,” *Gastroenterology and Hepatology from Bed to Bench*, vol. 9, no. 4, pp. 325–330, Sep. 2016, doi: 10.22037/ghb.2016.07.01.

[25] J. Loubinoux, J.-P. Bronowicki, I. A. C. Pereira, J.-L. Mougenel, and A. E. Faou, “Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases,” *FEBS Microbiology Ecology*, vol. 40, no. 2, pp. 107–112, May 2002, doi: 10.1111/j.1574-6941.2002.tb00942.x.

[26] A. C. Ouwheand et al., “Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study,” *Vaccine*, vol. 32, no. 4, pp. 458–463, Jan. 2014, doi: 10.1016/j.vaccine.2013.11.053.
[27] T. Cieplak, N. Soffer, A. Sulakvelidze, and D. S. Nielsen, “A bacteriophage cocktail targeting *Escherichia coli* reduces *E. coli* in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota,” *Gut Microbes*, vol. 9, no. 5, pp. 1–9, Aug. 2018, doi: 10.1080/19490976.2018.1447291.

[28] B. B. Hsu *et al.*, “Dynamic Modulation of the Gut Microbiota and Metabolome by Bacteriophages in a Mouse Model,” *Cell Host and Microbe*, vol. 25, no. 6, pp. 803-814.e5, Jun. 2019, doi: 10.1016/j.chom.2019.05.001.

[29] H. duo Bao *et al.*, “Alterations in the diversity and composition of mice gut microbiota by lytic or temperate gut phage treatment,” *Applied Microbiology and Biotechnology*, vol. 102, no. 23, pp. 10219–10230, Dec. 2018, doi: 10.1007/s00253-018-9378-6.

[30] C. J. M. Koning, D. M. A. E. Jonkers, E. E. Stobberingh, L. Mulder, F. M. Rombouts, and R. W. Stockbrügger, “The Effect of a Multispecies Probiotic on the Intestinal Microbiota and Bowel Movements in Healthy Volunteers Taking the Antibiotic Amoxycillin,” doi: 10.1111/j.1572-0241.2007.01547.x.

[31] S. M. Faber, “Treatment of abnormal gut flora improves symptoms in patients with irritable bowel syndrome,” *The American Journal of Gastroenterology*, vol. 95, no. 9, pp. 2533–2533, Sep. 2000, doi: 10.1111/j.1572-0241.2000.02781.x.

[32] V. R. Figliuolo *et al.*, “Sulfate-reducing bacteria stimulate gut immune responses and contribute to inflammation in experimental colitis,” *Life Sciences*, vol. 189, pp. 29–38, Nov. 2017, doi: 10.1016/j.lfs.2017.09.014.